AstraZeneca’s (AZN) Sell Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “sell” rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a report issued on Wednesday, Digital Look reports. They currently have a £115 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential downside of 3.72% from the company’s previous close.

Several other brokerages have also commented on AZN. Berenberg Bank restated a “buy” rating and issued a £160 price objective on shares of AstraZeneca in a report on Tuesday, July 28th. Citigroup boosted their target price on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group restated a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of £152.17.

Get AstraZeneca alerts:

Read Our Latest Report on AstraZeneca

AstraZeneca Trading Down 0.2%

Shares of AZN stock opened at £119.44 on Wednesday. AstraZeneca has a 1-year low of £107.84 and a 1-year high of £157.32. The firm has a market cap of £185.24 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The company has a 50-day moving average of £126.87 and a two-hundred day moving average of £137.23. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles

• Five stocks we like better than AstraZeneca
• Dutch Bros Sell-Off Creates a Growth Opportunity
• NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
• Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
• Medtronic’s Stars Are Aligning for a Price Recovery

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.